Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome.
about
Stress and visceral pain: from animal models to clinical therapiesPredicting disease risk using bootstrap ranking and classification algorithms.Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome.Review article: new receptor targets for medical therapy in irritable bowel syndromeThe treatment of irritable bowel syndromeStress-induced visceral pain: toward animal models of irritable-bowel syndrome and associated comorbidities.Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome.Psychopharmacological treatment and psychological interventions in irritable bowel syndrome.New treatments for irritable bowel syndrome in womenMedical management of irritable bowel syndrome in 2008: current and future directions.Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles.Pharmacological agents currently in clinical trials for disorders in neurogastroenterology.A treatment trial of acupuncture in IBS patientsCurrent and novel therapeutic options for irritable bowel syndrome management.Measuring irritable bowel syndrome patient-reported outcomes with an abdominal pain numeric rating scalePsychometric evaluation of patient-reported outcomes in irritable bowel syndrome randomized controlled trials: a Rome Foundation report.Pathogenesis, Experimental Models and Contemporary Pharmacotherapy of Irritable Bowel Syndrome: Story About the Brain-Gut Axis.Asimadoline in the treatment of irritable bowel syndrome.Investigational agents for the irritable bowel syndrome.Existing and emerging therapies for irritable bowel syndrome.Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome.New treatments for IBS.Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome.Current and emerging pharmacotherapeutic options for irritable bowel syndrome.Emerging drug for diarrhea predominant irritable bowel syndrome.Pharmacological Approach for Managing Pain in Irritable Bowel Syndrome: A Review Article.Editorial: is adequate relief fatally flawed or adequate as an end point in irritable bowel syndrome?Systematic review of modulators of benzodiazepine receptors in irritable bowel syndrome: is there hope?Randomized controlled study of efficacy and safety of drotaverine hydrochloride in patients with irritable bowel syndrome.Hospital readmissions in patients with inflammatory bowel disease.
P2860
Q30459512-9E0C96A2-9315-4173-9BBD-1BE3B2362DD9Q31129426-EBF4ECE2-C6E9-46CB-9B16-91593332A8AEQ33451900-429AAD7B-3401-4E78-AD91-3C2D71335A5AQ33959307-4D581ECB-930A-4310-9CB4-75E6AB02363FQ34409009-DE19B7E3-1F3E-4492-9DDA-E40C6A268926Q35087100-54A38383-D275-4E43-84D0-17875A5467FCQ36166972-DFB25EF1-8190-49D2-B775-E0CF3EA7251EQ36203967-4137D5AA-95F8-4676-9F2D-86760D9A5175Q37120300-8FC18386-558B-46C1-926A-FDED0D27D559Q37141316-D8FC2029-8E27-4018-A2CB-8B30DCE95767Q37164063-0140EC75-A27C-4A6B-8789-A699A1F424B3Q37200907-3492485C-BB20-4BCD-BC07-9F1B7DD230B9Q37223914-7E8E70A6-FE13-4C01-854F-B2433012C7B0Q37438547-02E7521B-5766-4C4F-8640-D338841DAC81Q37475265-2BA467F8-7C8A-408B-B0D8-710376F3152FQ37475280-D595A7C3-7343-4348-8225-E9D96772D14AQ37677017-EC08FFA7-F6A5-4589-A9DE-4FEF817572C3Q37784531-282F22CA-7A28-46F6-8963-A284125F3AC6Q37788218-A9211869-6933-4CBE-A85D-230655FF1BB0Q37857849-FFFF7E30-289A-4A4B-9B93-934BCA23C76CQ37954521-5C6F3A21-D58E-426A-8FC5-75550C539ECCQ38059436-A31AE856-2B6A-424C-B703-EFA01EDA95E7Q38102063-F5DA65D3-E527-404A-BE9E-173EE5DD088EQ38254747-5B856227-4930-4805-A60E-0471C98910CEQ38366814-11469016-058F-4CF6-A87D-4E784E54F7B1Q41392745-9775B5C6-2502-4F5B-A938-AD90E5974797Q42738877-9D01F754-330B-43C1-909E-9C45D6B737ABQ42967808-0EB7CF6E-7633-4790-BEF2-FC8C16E3CF82Q49213442-86627871-00D7-4E1C-82A2-2D778DCC3EE5Q53103154-917A9C05-95AC-4E84-8F96-EFDAA2DDBCCA
P2860
Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome.
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
name
Clinical trial: dextofisopam i ...... ting irritable bowel syndrome.
@ast
Clinical trial: dextofisopam i ...... ting irritable bowel syndrome.
@en
Clinical trial: dextofisopam i ...... ting irritable bowel syndrome.
@nl
type
label
Clinical trial: dextofisopam i ...... ting irritable bowel syndrome.
@ast
Clinical trial: dextofisopam i ...... ting irritable bowel syndrome.
@en
Clinical trial: dextofisopam i ...... ting irritable bowel syndrome.
@nl
prefLabel
Clinical trial: dextofisopam i ...... ting irritable bowel syndrome.
@ast
Clinical trial: dextofisopam i ...... ting irritable bowel syndrome.
@en
Clinical trial: dextofisopam i ...... ting irritable bowel syndrome.
@nl
P2093
P1476
Clinical trial: dextofisopam i ...... ting irritable bowel syndrome.
@en
P2093
Frissora CL
Leventer SM
Phillips J
Raudibaugh K
P304
P356
10.1111/J.1365-2036.2007.03566.X
P407
P577
2007-10-31T00:00:00Z